Last reviewed · How we verify
Fluticasone propionate 0.05% lotion
Fluticasone propionate is a topical corticosteroid that suppresses local inflammatory and immune responses in the skin by binding to glucocorticoid receptors.
Fluticasone propionate is a topical corticosteroid that suppresses local inflammatory and immune responses in the skin by binding to glucocorticoid receptors. Used for Inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses, Atopic dermatitis, Contact dermatitis.
At a glance
| Generic name | Fluticasone propionate 0.05% lotion |
|---|---|
| Sponsor | Fougera Pharmaceuticals Inc. |
| Drug class | Topical corticosteroid (Class III/IV potency) |
| Target | Glucocorticoid receptor |
| Modality | Small molecule |
| Therapeutic area | Dermatology |
| Phase | FDA-approved |
Mechanism of action
Fluticasone propionate is a potent synthetic glucocorticoid that penetrates the skin and binds to intracellular glucocorticoid receptors, leading to decreased production of inflammatory mediators, reduced immune cell infiltration, and suppression of local inflammatory cascades. This results in reduced erythema, pruritus, and other signs of dermatological inflammation. The 0.05% lotion formulation provides topical delivery with minimal systemic absorption when applied to intact skin.
Approved indications
- Inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses
- Atopic dermatitis
- Contact dermatitis
- Seborrheic dermatitis
Common side effects
- Local skin irritation or burning
- Skin atrophy (with prolonged use)
- Folliculitis
- Hypopigmentation
- Systemic corticosteroid effects (rare with topical use)
Key clinical trials
- A Randomized, Open-label, Comparative Study to Evaluate an Intermittent Dosing Regimen of Fluticasone Propionate 0.05% Cream (Twice Per Week) in Reducing the Risk of Relapse When Added to Regular Daily Moisturization Using PHYSIOGEL Lotion in Paediatric Subjects With Stabilized Atopic Dermatitis (PHASE4)
- Cutivate Lotion HPA Axis Pediatric Study (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Fluticasone propionate 0.05% lotion CI brief — competitive landscape report
- Fluticasone propionate 0.05% lotion updates RSS · CI watch RSS
- Fougera Pharmaceuticals Inc. portfolio CI